MGI/SuperGen’s Dacogen Is “Approvable” Pending Transfusion Data Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies expect to submit requested data to FDA early in the fourth quarter for the myelodysplastic syndromes therapy.